Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Dermira, Inc. (DERM) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/05/2019 8-K Quarterly results
Docs: "Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update"
08/07/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update"
05/07/2019 8-K Quarterly results
Docs: "Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update"
02/26/2019 8-K Quarterly results
11/07/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Dermira Reports Third Quarter 2018 Financial Results"
08/06/2018 8-K Quarterly results
Docs: "Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update"
05/03/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : May 3, 2018 DERMIRA, INC. Delaware 001-36668 27-3267680 275 Middlefield Road, Suite 150 Menlo Park, California 94025 Registrant's telephone number, including area code: 421-7200 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c...",
"Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update"
02/22/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update"
11/06/2017 8-K Quarterly results
Docs: "Dermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis"
08/07/2017 8-K Quarterly results
Docs: "Dermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update"
05/08/2017 8-K Form 8-K - Current report
02/28/2017 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "Dermira Reports Third Quarter 2016 Financial Results and Provides Corporate Update"
08/08/2016 8-K Form 8-K - Current report
05/10/2016 8-K Form 8-K - Current report
11/10/2015 8-K Quarterly results
Docs: "Dermira Reports Third Quarter 2015 Financial Results and Provides Corporate Update"
08/13/2015 8-K Quarterly results
Docs: "Dermira Reports Second Quarter 2015 Financial Results and Provides Corporate Update"
05/12/2015 8-K Quarterly results
Docs: "Dermira Reports First Quarter 2015 Financial Results and Provides Corporate Update Three late-stage programs continue to progress"
03/26/2015 8-K Quarterly results
Docs: "Dermira Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update DRM01 Phase 2b trial in acne to start April 2015 Conference call today at 4:30 p.m. Eastern Time"
11/12/2014 8-K Quarterly results
Docs: "Dermira Reports Third Quarter 2014 Financial Results and Provides Corporate Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy